Defined, Serum/feeder-Free Conditions for Expansion and Drug Screening of Primary B-acute Lymphoblastic Leukemia
Zhiwu Jiang,Di Wu,Wei Ye,Jianyu Weng,Peilong Lai,Pengcheng Shi,Xutao Guo,Guohua Huang,Qiuhua Deng,Yanlai Tang,Hongyu Zhao,Shuzhong Cui,Simiao Lin,Suna Wang,Baiheng Li,Qiting Wu,Yangqiu Li,Pentao Liu,Duanqing Pei,Xin Du,Yao,Peng Li
DOI: https://doi.org/10.18632/oncotarget.22466
2017-01-01
Oncotarget
Abstract:Functional screening for compounds represents a major hurdle in the development of rational therapeutics for B-acute lymphoblastic leukemia (B-ALL). In addition, using cell lines as valid models for evaluating responses to novel drug therapies raises serious concerns, as cell lines are prone to genotypic/phenotypic drift and loss of heterogeneity in vitro. Here, we reported that OP9 cells, not OP9-derived adipocytes (OP9TA), support the growth of primary B-ALL cells in vitro. To identify the factors from OP9 cells that support the growth of primary B-ALL cells, we performed RNA-Seq to analyze the gene expression profiles of OP9 and OP9TA cells. We thus developed a defined, serum/feeder-free condition (FI76V) that can support the expansion of a range of clinically distinct primary B-ALL cells that still maintain their leukemia-initiating ability. We demonstrated the suitability of high-throughput drug screening based on our B-ALL cultured conditions. Upon screening 378 kinase inhibitors, we identified a cluster of 17 kinase inhibitors that can efficiently kill B-ALL cells in vitro. Importantly, we demonstrated the synergistic cytotoxicity of dinaciclib/BTG226 to B-ALL cells. Taken together, we developed a defined condition for the ex vivo expansion of primary B-ALL cells that is suitable for high-throughput screening of novel compounds.